User profiles for P. Kadiyala
Pavan Kumar KadiyalaProfessor, Dr NTRUHS, Vijayawada, AP, India Verified email at asram.in Cited by 126 |
[HTML][HTML] Anaesthesia for electroconvulsive therapy: An overview with an update on its role in potentiating electroconvulsive therapy
PK Kadiyala, LD Kadiyala - Indian journal of anaesthesia, 2017 - journals.lww.com
Despite advances in pharmacotherapy, electroconvulsive therapy (ECT) remains a mainstay
treatment option in psychiatry since its introduction in 1930s. It can be used primarily in …
treatment option in psychiatry since its introduction in 1930s. It can be used primarily in …
Investor reaction to corporate event announcements: underreaction or overreaction?
P Kadiyala, PR Rau - The Journal of Business, 2004 - JSTOR
Two conflicting behavioral models, underreaction and overreaction, have been proposed to
explain long‐run abnormal returns following a variety of corporate events. We test …
explain long‐run abnormal returns following a variety of corporate events. We test …
IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response
FJ Núñez, FM Mendez, P Kadiyala… - Science translational …, 2019 - science.org
… (O and P) Tumor progression was evaluated by tumor size quantification of wt-IDH1 (O)
and mIDH1 (P) tumor sections at 14 and 21 DPI with or without IR treatment at the indicated …
and mIDH1 (P) tumor sections at 14 and 21 DPI with or without IR treatment at the indicated …
High-density lipoprotein-mimicking nanodiscs for chemo-immunotherapy against glioblastoma multiforme
P Kadiyala, D Li, FM Nuñez, D Altshuler, R Doherty… - ACS …, 2019 - ACS Publications
… We observed a ∼1.5-fold (p < 0.007) increase in the MS of mice after IR (MS: 43 dpi) and a
∼2.0-fold (p < 0.001) increase in the MS of mice after DTX-sHDL-CpG (MS: 55 dpi) treatment …
∼2.0-fold (p < 0.001) increase in the MS of mice after DTX-sHDL-CpG (MS: 55 dpi) treatment …
Systemic delivery of an adjuvant CXCR4–CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy
…, AV Andjelkovic, JV Gregory, P Kadiyala… - ACS …, 2022 - ACS Publications
… (N–P) Bar graphs represent levels of ICD marker HMGB1 in mouse glioma cells (RPA,
OL61, or Arf –/– ) after treatment with saline, AMD3100, IR (3 Gy), or AMD3100 + IR. (Q–S) Bar …
OL61, or Arf –/– ) after treatment with saline, AMD3100, IR (3 Gy), or AMD3100 + IR. (Q–S) Bar …
[HTML][HTML] Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy
JV Gregory, P Kadiyala, R Doherty, M Cadena… - Nature …, 2020 - nature.com
… by greater than five-fold (***p < 0.0001). f Internalized SPNPs colocalize with lysosomes to
a lesser extent than untargeted particles (*p = 0.0235). Data are presented as mean values ± …
a lesser extent than untargeted particles (*p = 0.0235). Data are presented as mean values ± …
[HTML][HTML] Immunosuppressive myeloid cells' blockade in the glioma microenvironment enhances the efficacy of immune-stimulatory gene therapy
N Kamran, P Kadiyala, M Saxena, M Candolfi, Y Li… - Molecular Therapy, 2017 - cell.com
Survival of glioma (GBM) patients treated with the current standard of care remains dismal.
Immunotherapeutic approaches that harness the cytotoxic and memory potential of the host …
Immunotherapeutic approaches that harness the cytotoxic and memory potential of the host …
[HTML][HTML] Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice
P Kadiyala, SV Carney, JC Gauss… - The Journal of …, 2021 - Am Soc Clin Investig
… We observed a 1.3-fold (P ≤ 0.001) increase in MS of mice in the AGI-5198–treated
group (MS: 43 dpi), and a 1.5-fold (P ≤ 0.001) increase in MS of mice in the AGI-5198+IR–treated …
group (MS: 43 dpi), and a 1.5-fold (P ≤ 0.001) increase in MS of mice in the AGI-5198+IR–treated …
Arginase 1 is a key driver of immune suppression in pancreatic cancer
…, W Yan, F Lima, A Bischoff, P Kadiyala… - Elife, 2023 - elifesciences.org
… P Kadiyala was supported by the Immunology training grant (T32- AI007413). D Salas-
Escabillas was supported by the Rackham Merit Fellowship and by the Cancer Biology Program …
Escabillas was supported by the Rackham Merit Fellowship and by the Cancer Biology Program …
WNT signaling in the tumor microenvironment promotes immunosuppression in murine pancreatic cancer
W Du, RE Menjivar, KL Donahue, P Kadiyala… - Journal of Experimental …, 2022 - rupress.org
Pancreatic ductal adenocarcinoma (PDA) is associated with activation of WNT signaling.
Whether this signaling pathway regulates the tumor microenvironment has remained …
Whether this signaling pathway regulates the tumor microenvironment has remained …